The microbiome therapeutics market is expected to reach USD 433.5 million by 2025, based on a new study by Grand View Research, Inc. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.
The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.
Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
- Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome
- Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT
- No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.
- It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline
- C. difficile dominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period
- North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities
- Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China
- Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome
- High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players